The efficacy of zotepine in schizophrenia: A meta-analysis of BPRS and improvement scale scores

International Journal of Psychiatry in Clinical Practice

Volumn 4, Issue 1, 2000, Pages 19-27

  Butler, Andrew ^a   Wighton, Andrew ^a   Welch, Claire P ^a   Tweed, Jack A ^a   Byrom, Bill D ^a   Reynolds, Chris ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Meta analysis; Schizophrenia; Zotepine

Indexed keywords

DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; SEROTONIN RECEPTOR; ZOTEPINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034111814     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500052048460     Document Type: Review

References (33)

1. Prakash A, Lamb HM (1998) Zotepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 9: 153-175.
2. Fleischhacker WW, Barnas C, Stuppäck C et al (1987) Zotepine in the treatment of negative symptoms in chronic schizophrenia. Pharmacopsychiatry 20: 58-60.
3. Needham PL, Atkinson J, Skill MJ, Heal DJ (1996) Zotepine: preclinical tests predict antipsychotic efficacy and an atypical profile. Psychopharmacol Bull 32: 123-128.
4. Fleischhacker WW, Hummer M (1997) Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. Drugs 53: 915-929.
5. Dieterle DM, Müller-Spahn F, Ackenheil M (1991) Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients. Fortschr Neurol Psychiatr 59: 18-22.
6. Müller-Spahn F, Dieterle DM, Ackenheil M (1991) Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms - results of an open and a double blind controlled study. Fortschr Neurol Psychiatr 59: 30-35.
7. Wetzel H, von Bardeleben U, Holsboer F, Benkert O (1991) Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness. Fortschr Neurol Psychiatr 59: 23-29.
8. Petit M, Raniwalla J, Tweed J et al (1996) A comparison of an atypical and typical antipsychotic: zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 32: 81-87.
9. Fleischhacker WW, Barnas C, Stuppäck C et al (1989) Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 25: 97-100.
10. Leysen JE, Janssen PMF, Heylen L et al (1998) Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects. Int J Psychiatr Clin Pract 2 (suppl 2): S3-S17.
11. Costall B, Naylor RJ (1986) Neurotransmitter hypothesis of schizophrenia. In The psychopharmacology and treatment of schizophrenia (British Association for Psychopharmacology Monograph No. 8) 132-165. Oxford Medical Publications, Oxford.
12. Kanba S, Yagi G, Oguchi E et al (1991) Neuropharmacology of zotepine, an antimanic drug: A potent blocker of D2 and 5HT2 receptors of human brain. Japan J Psychiatry Neurology 45: 133-134.
13. Risch SC (1996) Pathophysiology of schizophrenia and the role of the newer antipsychotics. Pharmacotherapy 16: 11-14.
14. Schotte A, Janssen PF, Gommeren W et al (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol (Berl) 124:57-73.
15. Tricklebank MD (1996) The antipsychotic potential of subtype-selective 5HT receptor ligands based on interactions with mesolimbic dopamine systems. Behav Brain Res 73: 15-17.
16. Abi Dargham A, Laruelle M, Aghajanian CK et al (1997) The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiatry Clin Neurosci 9: 1-17.
17. Pickar D (1991) Prospects for pharmacotherapy of schizophrenia. Lancet 345: 557-562.
18. Ohno Y, Ishida K, Ikeda K et al (1994) Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test. Pharmacol Biochem Behav 49: 19-23.
19. Dieterle DM, Ackenheil M, Müller-Spahn F et al (1987) Zotepine, a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiatry 20: 52-57.
20. Von Bardeleben U, Benkert O, Holsboer F (1997) Clinical and neuroendocrine effects of zotepine a new neuroleptic drug. Pharmacopsychiatry 20: 28-34.
21. Klieser E, Lehmann E, Tegeler J (1991) Double-blind comparison of 3 × 75 mg zotepine and 3 × 4 mg haloperidol in acute schizophrenics. Fortschr Neurol Psychiatr 59: 14-17.
22. Whitehead A, Whitehead J (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Statistics in Medicine 10: 1665-1677.
23. Carman J, Peuskins J, Vangeneugden A (1995) Risperidone in the treatment of negative symptoms of schizophrenia. A meta-analysis. Int Clin Psychopharmacol 10: 207-213.
24. De Oliveira IR, Miranda Scippa AM, de Sena EP et al (1996) Risperidone versus haloperidol in the treatment of schizophrenia: A meta-analysis comparing their efficacy and safety. J Clin Pharm Ther 21: 349-358.
25. Song F (1997) Risperidone in the treatment of schizophrenia: A meta-analysis of randomized controlled trials. J Psychopharmacol 11: 65-71.
26. Barnas C, Stuppäck CH, Miller C et al (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs haloperidol. In t J Clin Psychopharmacol 7: 23-27.
27. Nishizono M (1994) A comparative trial of zotepine, chlorpromazine and haloperidol in schizophrenic patients. Neuropsychopharmacol 10 (suppl): 30.
28. Sarai K, Okada M (1987) Comparison of efficacy of zotepine and thioxetene in schizophrenia in a double-blind study. Pharmacopsychiatry 20: 38-46.
29. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10: 799-812.
30. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, revised. (DSM-III-R). American Psychiatric Association, Washington DC.
31. World Health Organization (1994) International classification of diseases 10th edn. World Health Organization, Geneva.
32. Meyer Lindenberg A, Gruppe H, Bauer U et al (1997) Improvement of cognitive function in schizophrenia patients receiving clozapine or zotepine: Results from a double-blind study. Pharmacopsychiatry 30: 35-42.
33. Jones B, Jarvis P, Lewis JA, Ebbutt A (1996) Trials to assess equivalence: the importance of vigorous methods. Br Med J 313: 36-39.